LOS ANGELES, April 26, 2018 /PRNewswire/ --
GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA"), an
immuno-oncology biotechnology company focused on innovative
treatments based on the company's proprietary platforms, today
announced the addition of Federica
O'Brien, CPA to GT Biopharma's board of directors effective
immediately. Ms. O'Brien is expected to chair the Company's audit
committee.
"We are delighted to welcome Freddi to our board of directors
and look forward to the impact her invaluable experience as a CPA,
biopharmaceutical chief financial officer and auditor will have on
the company. Her skills will be a critical asset as we move
towards a NASDAQ uplisting and other company initiatives," said
Shawn M. Cross, Chairman and Chief
Executive Officer of GT Biopharma.
At both private and public life science companies, Ms. O'Brien
has demonstrated financial and operational leadership, and is
experienced in raising capital and building infrastructures needed
to support corporate growth and regulatory compliance. Further, Ms.
O'Brien began her career at professional service accounting
firms.
"This is a remarkable time for the development of new treatments
for cancer patients with limited treatment options, and GT
Biopharma has the potential to deliver long-term growth and make a
significant impact delivering on these unmet medical needs," said
Ms. O'Brien. "I'm delighted to work with this accomplished
team."
Ms. O'Brien has held the Chief Financial Officer position at
Complexa Inc., Cerecor Inc., and Cardiokine, Inc., and was
Corporate Controller at Barrier Therapeutics, Inc. In
addition to her position as CFO at Cervilenz, Inc., Ms. O'Brien
held the position of Chief Operating Officer; she led the extension
of the patent portfolio worldwide and was influential in obtaining
CE marking and ISO 13485 certification for a women's healthcare
device. Earlier in her career, Ms. O'Brien was CFO of
Infonautics, Inc., a publicly-held technology-based company.
Before specializing in life sciences and technology
companies, Ms. O'Brien spent over fifteen years in professional
service accounting firms, including PricewaterhouseCoopers, where
she was dedicated to high growth companies in multiple industries,
including the pharmaceutical industry.
Ms. O'Brien received her B.A. in Accounting from Rutgers University in 1980 and is a member of the
American Institute of Certified Public Accountants and the
Association of Bioscience Financial Officers.
About GT Biopharma, Inc.
GT Biopharma, Inc. is an immuno-oncology biotechnology company
focused on innovative treatments based on the company's proprietary
Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and
TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms.
GT's lead oncology drug candidate, OXS-1550 (DT2219) is a novel
bispecific scFv recombinant fusion protein-drug conjugate composed
of the variable regions of the heavy and light chains of anti-CD19
and anti-CD22 antibodies and a modified form of diphtheria toxin as
its cytotoxic drug payload. OXS-1550 has demonstrated success in
early human clinical trials in patients with relapsed/refractory
B-cell lymphoma or leukemia. In addition, GT's TriKE platform will
address a number of cancer types. GT's nervous system platform is
focused on acquiring or discovering and patenting late-stage,
de-risked, and close-to-market improved treatments for nervous
system diseases (Neurology and Pain) and shepherding them through
the approval process to the NDA. GT Biopharma's neurology products
currently include PainBrake, as well as treatments for the symptoms
of myasthenia gravis, and motion sickness.
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the effectiveness of the Company's products, the
potential outcome of clinical studies, the future success of
development activities, the future growth and operating and
financial performance of the Company and the possibility of the
Company uplisting to NASDAQ. Factors which could cause actual
results to differ materially from these forward-looking statements
include such factors as the Company's ability to accomplish its
business initiatives, obtain regulatory approval and protect its
intellectual property; significant fluctuations in marketing
expenses and ability to achieve or grow revenue, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products; the
Company's ability to meet the applicable NASDAQ uplisting
requirements, and other information that may be detailed from time
to time in the Company's filings with the United States Securities
and Exchange Commission. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Contact:
Westwicke Partners
John Woolford
+1-(443)-213-0506
john.woolford@westwicke.com
SOURCE GT Biopharma Inc.